BHVN
Biohaven Ltd.
There isn't enough reported data to score BHVN yet.
LLY
Eli Lilly and Company
LLY's fundamentals are strong: revenue grew 46% and it turned 23% of its revenue into free cash flow. At 46x earnings, it's trading in line with its usual 48x. Analysts expect that strong growth to continue.
BHVN Fundamentals
| Metric | Status |
|---|---|
| Weak | |
| Weak | |
| Unavailable | |
| Unavailable |
BHVN's revenue and profitability are currently weak. There isn't enough data to rate its cash flow and balance sheet.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
BHVN PE Valuation
BHVN has no meaningful PE right now: it lost money over the past year.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
BHVN Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| -- | |
| Limited | |
| Low |
Analysts expect BHVN's losses to shrink, with revenue growing. However, they disagree widely on these estimates.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
BHVN Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$3.76 | +$3.73 |
| Q2 2026 | -$4.54 | +$3.01 |
| Q1 2026 | -$5.57 | +$3.68 |
| Q4 2025 | -$6.86 | +$2.42 |
| Q3 2025 | -$7.49 | +$1.93 |
| Q2 2025 | -$7.55 | +$1.67 |
| Q1 2025 | -$9.25 | -$2.35 |
| Q4 2024 | -$9.28 | -$3.55 |
BHVN is still losing money, but far less than before: $3.76 per share over the past year, against $15.26 at its worst in mid-2021.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over BHVN on earnings quality, reporting a profit while its opponent remains loss making.
BHVN Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2021 | $92.9M | +858% |
| Q1 2021 | $43.8M | +3707% |
LLY has the stronger quarterly revenue trend. Revenue is down 100% for BHVN versus up 39% for LLY.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2021 | -185% | +1471 points |
| Q1 2021 | -538% | +12576 points |
| Q4 2020 | -486% | N/A |
| Q3 2020 | -924% | N/A |
| Q2 2020 | -1656% | N/A |
| Q1 2020 | -13114% | N/A |
BHVN's operating margin was −185% last quarter, up 1471 points from the same quarter a year ago.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY's revenue has grown year over year for 14 quarters in a row: $24.4B last quarter, up 39% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY's operating margin was 34% last quarter, down 6.6 points from the same quarter a year ago.
BHVN Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$107M | +$38.7M |
| Q2 2026 | -$85.6M | +$82.6M |
| Q1 2026 | -$149.9M | +$15.7M |
| Q4 2025 | -$130.7M | +$40.1M |
| Q3 2025 | -$145.7M | -$3.8M |
| Q2 2025 | -$168.2M | +$2.6M |
| Q1 2025 | -$165.6M | -$62.5M |
| Q4 2024 | -$170.8M | -$55.4M |
BHVN has burned cash in almost every quarter: −$473M over the past year, against −$650M the year before.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over BHVN on cash generation, producing positive trailing cash flow while its opponent burns cash.
BHVN Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.3% | +404K shares |
| 1 year | +48% | +48.7M shares |
| 3 years | +121% | +82.8M shares |
| 5 years | +211% | +103M shares |
| Available history | +188% | +98.6M shares |
BHVN has 151M diluted shares, up 48% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2022 | — |
| Q1 2022 | — |
| Q4 2021 | — |
| Q3 2021 | — |
| Q2 2021 | — |
| Q1 2021 | — |
| Q4 2020 | — |
| Q1 2020 | — |
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over BHVN on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
BHVN Net Leverage
BHVN's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
BHVN Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 52.6 | Neutral |
| Stochastic | 52.5 | Neutral |
BHVN's weekly RSI is 53 (neutral) and its Stochastic is 52 (neutral).
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
BHVN PE vs Healthcare Sector
BHVN has no meaningful PE right now: it lost money over the past year.
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
BHVN Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $13.3 | 5.6% above |
| 20 week MA | $14.1 | 0.2% below |
| 50 week MA | $12.2 | 16% above |
| 100 week MA | $16.8 | 16% below |
| 200 week MA | $24.8 | 43% below |
BHVN's trend is mixed: it's above two of its five weekly moving averages, and 43% below its 200-week average.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over BHVN on trend strength, trading above more of its moving averages.
BHVN Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2022 | $7.30 | $13.7 | +88% |
| 2023 | $13.7 | $42.8 | +212% |
| 2024 | $42.8 | $36.7 | -14% |
| 2025 | $36.7 | $11.2 | -70% |
| 2026 YTD | $11.2 | $14.1 | +26% |
BHVN's yearly returns have swung widely, from +212% in 2023 to −70% in 2025. It's up 26% so far in 2026.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over BHVN on returns for 2026, with the stronger performance.